Logo

BMS Reports Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC

Share this

BMS Reports Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC

Shots:

  • The P-III CheckMate -648 trial involves assessing Opdivo (nivolumab) + CT or Opdivo (3 mg/kg- q2w) + Yervoy (1 mg/kg- q6w up to 24mos.) in patients with unresectable advanced or metastatic ESCC
  • Results: Both the combinations demonstrated OS benefits in PD-L1 positive and all-randomized populations
  • Additionally- Opdivo + CT met its 1EP of PFS while Opdivo + Yervoy failed to meet its 1EPs of PFS. The safety profiles of Opdivo and the combination of Opdivo and Yervoy were consistent with previously reported studies

  Ref: BMS | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions